fxstreet.com 08 Feb, 2021 11:45 am

Atossa Therapeutics Inc falls to close the week after notable gain on some big news

Atossa Therapeutics Inc falls to close the week after notable gain on some big news
NASDAQ:ATOS has finally given its investors the news they wanted to hear and the stock reacted appropriately on Thursday, spiking by nearly 50%. On Fr

The study revealed a 74% reduction in tumor activity for breast cancer patients.The reports showed that the patients exhibited an average reduction of 74% in tumor activity which brought it to levels that are indicative of long-term survival amongst breast cancer patients.If or perhaps when this is granted, expect there to be a high demand for the drug as breast cancer topped the list in 2020 as the most frequently diagnosed form of cancer with over 279,000 cases and 42,000 deaths in the United States alone.Atossa Therapeutics announced that it ended its clinical trial early on a blowout success rate.

The catalyst for the surge in price was Atossa Therapeutics’ announcement that it had prematurely ended its Australian Phase 2 clinical trials with what it called ‘substantially positive results’.FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements.

Read full story at fxstreet.com